Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma

NCT01972347 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Dabrafenib
DRUG: Trametinib

Sponsor

Melanoma Institute Australia